Type 1 Hides Two Metabolic Faces
Endocrinologists see wide insulin secretion ranges in autoantibody positive patients before clinical diabetes hits. Some lose beta cells fast while others maintain function years longer. Genetic scores might explain this split. Researchers tested type 2 diabetes risk genes in preclinical type 1 diabetes patients. The results were published in the Diabetes.
Massive TrialNet Cohort Breaks Patterns
Study analyzed 4,324 islet autoantibody positive participants from TrialNet Pathway to Prevention study. Everyone had genome-wide genotyping plus oral glucose tolerance testing. C-peptide area under curve sorted patients into five groups from highest to lowest insulin secretion. Both T2D genetic risk score and T1D-GRS2 differed significantly across these groups.
High Secretors Carry T2D Protection
Highest C-peptide AUC group showed highest T2D-GRS versus lowest group. They had lower T1D-GRS2 too. High secretors carried higher BMI z-score, more insulin resistance, older age at testing. Fewer were male or had multiple autoantibodies including IA-2 or insulin antibodies.
Genes Dictate Progression Speed
T1D-GRS2 predicted stage 3 clinical diabetes across all C-peptide groups consistently. T2D-GRS sped progression in all but lowest C-peptide secretors. Type 2 genetic burden shaped metabolic path and timing to diagnosis.
Test Both Scores in Prediabetes
Genetic panels should include T2D-GRS for autoantibody positive patients. High T2D score flags slower progressors who need monitoring not immediate intervention. Low scores demand close watch for rapid decline.
Target T2D Pathways for Protection
Type 2 mechanisms might preserve beta cells in genetic high secretors. GLP1 agonists or insulin sensitizers deserve prevention trials now. Findings reshape risk counseling completely.
Personalize Type 1 Prevention
Metabolic heterogeneity demands genetic guided strategies. Slow progressors buy time for immune therapies. Fast decliners need urgent beta cell protection.